Jazz Pharmaceuticals JAZZ Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's pre-tax income?
- Jazz Pharmaceuticals (JAZZ) reported pre-tax income of $299.2M in Q1 2026.
- How has Jazz Pharmaceuticals's pre-tax income changed year-over-year?
- Jazz Pharmaceuticals's pre-tax income increased by 372.5% year-over-year, from -$109.8M to $299.2M.
- What is the long-term trend for Jazz Pharmaceuticals's pre-tax income?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's pre-tax income has grown at a 60.9% compound annual growth rate (CAGR), from -$112.84M to $470.35M.
- What does pre-tax income mean?
- Total profit before accounting for income tax payments.
- How do you interpret pre-tax income?
- A strong pre-tax income indicates robust overall financial health and operational success.
- How does pre-tax income compare across companies?
- Standard financial metric used to compare profitability across different tax regimes.